Tag: BARDA

Watchdog office says ‘reasonable grounds’ to believe ouster of vaccine official was retaliatory, his lawyers say

Washington Post logoThe Office of Special Counsel said it would recommend Rick Bright be reinstated during its investigation, according to his lawyers

The Office of Special Counsel has determined there are “reasonable grounds” to believe a former top vaccine official was removed from his post last month for retaliatory reasons and plans to recommend the Department of Health and Human Services reinstate him while it investigates, the official’s lawyers said Friday.

Rick Bright, former director of the Biomedical Advanced Research and Development Authority, was removed April 20 after having served as BARDA director for nearly four years. He was reassigned to a narrower role at the National Institutes of Health that HHS touted as part of a “bold new plan” to improve testing to defeat covid-19, the disease caused by the coronavirus.

Bright filed a whistleblower complaint this week that alleged he was reassigned because he resisted pressure from the department’s political leadership to make “potentially harmful drugs widely available,” including chloroquine and hydroxychloroquine. President Trump has repeatedly pushedboth as possible coronavirus cures. Continue reading.

Whistleblower alleges Trump administration ignored coronavirus warnings

Axios logoRick Bright, the former director of the U.S. Biomedical Advanced Research and Development Authority (BARDA), filed a whistleblower complaint Tuesday alleging that the Department of Health and Human Services failed to take early action to mitigate the threat of the novel coronavirus.

Flashback: Bright said last month he believes he was ousted after clashing with HHS leadership over his attempts to limit the use of hydroxychloroquine to treat the coronavirus.

What’s new: In his complaint, Bright claims he was excluded from an HHS meeting on the coronavirus in late January after he “pressed for urgent access to funding, personnel, and clinical specimens, including viruses” to develop treatments for the coronavirus should it spread outside of Asia.

  • Bright alleges it “became increasingly clear” in late January that “HHS leadership was doing nothing to prepare for the imminent mask shortage.”
  • Bright claims he “resisted efforts to fall into line with the Administration’s directive to promote the broad use of chloroquine and hydroxychloroquine and to award lucrative contracts for these and other drugs even though they lacked scientific merit and had not received prior scientific vetting.”
  • He adds that “even as HHS leadership began to acknowledge the imminent shortages in critical medical supplies, they failed to recognize the magnitude of the problem, and they failed to take the necessary urgent action.” Continue reading.